Breaking News Instant updates and real-time market news.

AMGN

Amgen

$189.44

-0.26 (-0.14%)

06:10
09/15/17
09/15
06:10
09/15/17
06:10

Amgen: FOURIER analysis shows Repatha reduces cardiovascular events

Amgen announced that a new analysis of the cardiovascular outcomes study, or FOURIER, demonstrated that lowering low-density lipoprotein cholesterol, or LDL-C, levels with Repatha significantly and consistently reduced cardiovascular events in patients with and without diabetes at baseline. The analysis showed that diabetes was independently associated with a substantially increased risk of cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease. Patients with diabetes tended to have a greater absolute risk reduction of cardiovascular events with Repatha treatment because of their heightened baseline risk. Consistent with recent trials of more intensive LDL lowering, Repatha has not shown an effect on cardiovascular mortality.1-5 The analysis also showed that Repatha was not associated with an increased risk of new-onset diabetes or worsening glycemia over a median of 2.2 years of follow-up in patients without diabetes or pre-diabetes. Additionally, no new safety concerns were identified in this analysis. The results were presented today at the 53rd Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal and simultaneously published in The Lancet Diabetes & Endocrinology.

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

AMGN Amgen
$189.44

-0.26 (-0.14%)

09/14/17
RBCM
09/14/17
INITIATION
Target $192
RBCM
Sector Perform
Amgen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Amgen with a Sector Perform and an $192 price target.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $193
PIPR
Overweight
Amgen still has long way to go in asthma, says Piper Jaffray
After last night's Phase 2 trial data of Amgen's (AMGN) tezepelumab in severe asthma, Piper Jaffray analyst Christopher Raymond says the drug "looks to be in the ballpark but still numerically short of the mark" when compared with Regeneron's (REGN) Dupixent's Phase 2 profile. He thinks full Phase 3 data will be the ultimate determinant of the relative merits of each mechanism and reminds investors that such data have not been seen for either drug. In a research note titled, "Tezepelumab Phase 2 Asthma Data Gets Amgen in the Game, But Still a Long Way to Go," James keeps an Overweight rating on Amgen, while noting tezepelumab, with Phase 3 data likely a few years out, is not in his valuation model.
09/07/17
SBSH
09/07/17
NO CHANGE
Target $575
SBSH
Buy
Regeneron asthma treatment still looks better than Amgen's, says Citi
Citi analyst Robyn Karnauskas says that while Amgen's (AMGN) and AstraZeneca's (AZN) asthma data is encouraging, Regeneron's (REGN) dupilumab appears to have better lung function profile in cross trial comparison. On a key endpoint of lung function improvement, Amgen's Tezepelumab does not appear to be providing a lot of benefit, Karnauskas tells investors in a research note. She notes that dupilumab in its phase 3 trial showed 12% improvement on lung function. Regeneron's asthma drug "is ahead and potentially better," Karnauskas writes. She keeps a Buy rating on Regeneron with a $575 price target.

TODAY'S FREE FLY STORIES

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

10:45
01/19/18
01/19
10:45
01/19/18
10:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$16.24

-0.535 (-3.19%)

10:35
01/19/18
01/19
10:35
01/19/18
10:35
Hot Stocks
Former GE vice chairman Wright says major issue is liabilities on balance sheet »

Speaking in a CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:35
01/19/18
01/19
10:35
01/19/18
10:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

NINE

Nine Energy Services

10:31
01/19/18
01/19
10:31
01/19/18
10:31
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

10:30
01/19/18
01/19
10:30
01/19/18
10:30
General news
U.S. January consumer confidence slid 1.5 points to 94.4 »

U.S. January consumer…

PAYC

Paycom

$89.86

0.74 (0.83%)

, ALRM

Alarm.com

$39.43

1.16 (3.03%)

10:29
01/19/18
01/19
10:29
01/19/18
10:29
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

$89.86

0.74 (0.83%)

ALRM

Alarm.com

$39.43

1.16 (3.03%)

CA

CA Technologies

$34.19

-0.28 (-0.81%)

RHT

Red Hat

$125.41

-0.06 (-0.05%)

ORCL

Oracle

$50.43

0.2 (0.40%)

SSNC

SS&C

$49.94

0.23 (0.46%)

VMW

VMware

$136.19

0.56 (0.41%)

CTXS

Citrix

$91.38

0.19 (0.21%)

MSFT

Microsoft

$90.10

-0.04 (-0.04%)

SYMC

Symantec

$27.25

-0.27 (-0.98%)

PANW

Palo Alto Networks

$157.60

-0.22 (-0.14%)

APTI

Apptio

$24.23

0.23 (0.96%)

CHKP

Check Point

$103.20

-0.37 (-0.36%)

NICE

Nice

$93.83

1.2 (1.30%)

SPLK

Splunk

$91.43

0.86 (0.95%)

RNG

RingCentral

$53.55

0.35 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

10:25
01/19/18
01/19
10:25
01/19/18
10:25
General news
The Michigan sentiment drop to a 6-month low of 94.4 »

The Michigan sentiment…

URG

UR-Energy

$0.72

-0.0279 (-3.72%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
UR-Energy to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
Leerink healthcare analysts hold an analyst/industry conference call »

Healthcare Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

  • 18

    Mar

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

, ATHN

athenahealth

$125.53

-0.65 (-0.52%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

IPCI

Intellipharmaceutics

$0.80

-0.02 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 02

    Feb

  • 06

    Feb

Z

Zillow

$43.97

-0.57 (-1.28%)

, ZG

Zillow

$43.86

-0.49 (-1.10%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

Z

Zillow

$43.97

-0.57 (-1.28%)

ZG

Zillow

$43.86

-0.49 (-1.10%)

BLMN

Bloomin' Brands

$21.96

0.02 (0.09%)

PH

Parker-Hannifin

$210.94

0.4 (0.19%)

MKC

McCormick

$100.10

-2.81 (-2.73%)

WNS

WNS Holdings

$44.30

-0.98 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 26

    Feb

NKE

Nike

$66.12

2.0086 (3.13%)

, ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$66.12

2.0086 (3.13%)

ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

CMG

Chipotle

$338.74

1.21 (0.36%)

FL

Foot Locker

$49.49

0.8999 (1.85%)

PM

Philip Morris

$107.12

2.05 (1.95%)

MO

Altria Group

$71.38

1.35 (1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 01

    Feb

  • 06

    Feb

ADT

ADT Inc.

, APO

Apollo Global

$34.07

-1.005 (-2.87%)

10:22
01/19/18
01/19
10:22
01/19/18
10:22
Syndicate
Breaking Syndicate news story on ADT Inc., Apollo Global »

ADT Inc. opens at $12.65,…

ADT

ADT Inc.

APO

Apollo Global

$34.07

-1.005 (-2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 19

    Jan

NSPR

InspireMD

$0.17

-0.0019 (-1.11%)

10:21
01/19/18
01/19
10:21
01/19/18
10:21
Hot Stocks
InspireMD reports independent publication highlighting advantages of CGuard EPS »

InspireMD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ODP

Office Depot

$3.51

0.01 (0.29%)

10:20
01/19/18
01/19
10:20
01/19/18
10:20
Options
Defensive option play in Office Depot »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
01/19/18
01/19
10:20
01/19/18
10:20
General news
Treasury Action: yields paused at highs after surging »

Treasury Action: yields…

10:18
01/19/18
01/19
10:18
01/19/18
10:18
Conference/Events
RBC Capital technology analysts hold an analyst/industry conference call »

Technology Analysts…

$NSD

NASDAQ Market Internals

10:17
01/19/18
01/19
10:17
01/19/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
01/19/18
01/19
10:16
01/19/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/19/18
01/19
10:15
01/19/18
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

FAZ

Direxion Financial Bear 3x

$10.45

-0.1438 (-1.36%)

10:10
01/19/18
01/19
10:10
01/19/18
10:10
Options
Direxion Daily Financial Bear 3X Shares draws a notable option block »

Direxion Daily Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NINE

Nine Energy Services

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

COLD

Americold Realty Trust

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Americold Realty Trust »

Americold Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

QRVO

Qorvo

$68.76

-1.92 (-2.72%)

10:05
01/19/18
01/19
10:05
01/19/18
10:05
Technical Analysis
Technical Take: Qorvo drops, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:04
01/19/18
01/19
10:04
01/19/18
10:04
General news
Potential government shutdown not doing much to rattle market »

Stock futures were a bit…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.